Company intelligence / Profile preview

Winteler

Warrington, Pennsylvania, United Stateswinteler.ch ↗

Ownership: Private
Employees: ~14
Development stage: Other

Overview

Windtree Therapeutics develops therapies for critical cardiovascular and pulmonary conditions. Its lead asset istaroxime has shown positive Phase II results in early cardiogenic shock. The company also has approved products such as Surfaxin/lucinactant for RDS in premature infants and continues to develop its proprietary KL4 surfactant technology. In early 2025 it adopted a new strategy to acquire revenue-generating assets from small biotechs with FDA-approved products.

Therapeutic areas: Infectious DiseasesPulmonologyCardiovascular
Modalities: Small moleculeProteinDrug-device combination
Industry: Biotech

Partnerships

Lee's Pharmaceutical (Greater China licensing partnership)Evofem Biosciences (license/supply agreement for PHEXXI)Chang Gung University collaboration on SERCA research

Beyond the preview

Go deeper on Winteler.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Winteler.

Explore the full profile